Apexigen, Inc.: auditor change — Apexigen reports positive Phase 2 data for sotigalimab in liposarcoma; mPFS 12.45 mo

Apexigen, Inc.

Sotigalimab + doxorubicin achieved median PFS of 12.45 months in liposarcoma patients vs historical <5 months for doxorubicin alone.
Apexigen plans to expand LPS cohort by 10 patients to inform potential Phase 3 registration-enabling trial.
Favorable safety profile observed; data supports further development in first-line liposarcoma.
Study is investigator-sponsored trial in collaboration with Columbia University (Gary Schwartz, PI).

item 4.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Apexigen, Inc. engaged Moss Adams LLP as its auditor.

Action: engagement
Auditor: Moss Adams LLP

Exact text from the filing

On November 8, 2022, the Audit Committee approved the engagement of Moss Adams LLP as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2022.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Apexigen, Inc. dismissed Marcum LLP as its auditor.

Action: dismissal
Auditor: Marcum LLP
Successor: Moss Adams LLP

Exact text from the filing

On November 8, 2022, the audit committee of the board of directors (the “Audit Committee”) of Apexigen, Inc. (the “Company”), dismissed Marcum LLP (“Marcum”), the Company’s independent registered public accounting firm prior to the Company’s business combination transaction that closed on July 29, 2022 (the “Business Combination”).

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0000950170-22-024985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.